(Finance) – PharmaNutraa company listed on Euronext STAR Milan and active in the sector of mineral supplements and medical devices for muscles and joints, closed the 2023 with Revenues from sales consolidated amounts of 100.2 million euros, recording a growth of 21.1% compared to the previous year. The Gross Operating Profit stands at 26.5 million euros (24.4 million in 2022), equal to a margin of 26% (29.2% in 2022) on total revenues, with a growth of approximately 8.7% compared to previous financial year.
The Net income amounts to 12.8 million euros, compared to 15.1 million at 31 December 2022. The net result for the period excluding non-recurring components, represented by the tax charge, amounts to 15.5 million euros.
“Concluding another year with more than positive results is already very important in itself, doing so in a historical period in which the company has invested means and resources to increase its business in the long term, both in Italy and abroad, it is an exceptional result in all respects”, commented the president Andrea Lacorte.
There Net Financial Position of 2023 records a reduction of €13.3 million compared to 31 December 2022 due to the investments made and presents a negative balance of €2.6 million compared to the positive balance of €10.6 million in the previous year. There liquidity generated by operational management amounts to euro 12.1 million.
The Board of Directors has resolved to propose to the forthcoming Shareholders’ Meeting the distribution of a dividend of 0.85 euros (+6.3% compared to the 2022 dividend) for each entitled share (for a maximum total of 8,172,743 euros), with ex-dividend date of coupon no. 7 on 6 May 2024, date of legitimacy for payment (record date) on 7 May 2024 and date for payment of the dividend on 8 May 2024.
PharmaNutra explains that the 2024 it will be “a challenging year both for maintaining the organic growth of the recurring business and for the development of the new projects launched in 2023 (Cetilar Nutrition, Pharmanutra Usa and Pharmanutra Espana)” and foresees a first quarter 2024 “in line with that of the previous year due to the dynamics linked to the changed inventory management policies of the Italian distribution channel and the dynamics of acquiring orders from abroad”.